Page 45 oncology will be a part of this to co-ordinate patient follow up and improve outcomes . Figure 41 below summarises these challenges .
Figure 41 : Challenges
Clinical
Economic
Scientific
• Limited uptake beyond core specialties
• Resistance from surgeons to adopt new technologies / techniques
• Reluctance to swap from systems they were trained on .
• Clinical benefits unproven and not yet quantified
• High risk oncology procedures may see slower penetration
• High upfront capital costs in addition to high per procedure cost
• Additional infrastructure required to sterilise instruments between surgeries
• Budget-constrained healthcare systems in Europe and Asia
• Innovation stifled by cost constraints
• Instrument degradation during reprocessing
• Closed system architecture promotes information islands within the OR
Source : goetzpartners Research
Future outlook
Innovation should see robotic surgery adopted as SoC across surgery
The ability of robotic-assisted surgery to extend the advantages of laparoscopy should drive its adoption as the SoC ( costs permitting ) in all but a few specialist situations . We are starting to see this in more complex surgeries already such as oesophagectomy and transoral surgeries . Although some surgeons may initially resist adoption , the increased safety and efficiency of robotic surgery means that the main barrier to adoption is cost . The need to remove smaller cancers due to earlier diagnosis will require more precise surgery in order to minimise collateral damage to the surrounding organs and tissue . This can be achieved through the use of robotic systems , which should help drive its widespread adoption in oncology .
Figure 42 : Present and future surgical oncology landscape
Source : goetzpartners Research , Created with BioRender . com
$ 5bn current market only represents < 5 % of the potential opportunity worldwide
Significant market opportunity The potential for robotic surgery is considerable . The market is currently valued at $ 5bn and projected to reach $ 20bn by 2030E , thus far the technology has only been widely adopted in urology and gynaecology in the US , accounting for around 2 % of the total potential procedures worldwide . As the
Please see analyst certifications , important disclosure information , and information regarding the status of analysts on pages 91-94 of this research report .